
Background and Objectives: EUS-guided fine-needle aspiration (EUS-FNA) using a 19-gauge FNA needle can safely obtain sufficient tissue samples for the evaluation of lymphadenopathy. FNB needles can also provide adequate tissue, and 22-gauge needles are generally easier to puncture than 19-gauge needles. This study aimed to compare the diagnostic performance of 19-gauge FNA and 22-gauge FNB needles for the diagnosis of lymphadenopathy. Methods: Among the 411 patients with lymphadenopathy, 221 underwent an EUS-FNA procedure using 19-gauge FNA or 22-gauge FNB needles. Patient characteristics, puncture procedures, and the accuracy of the cytological and histological diagnoses of lymphadenopathy were analyzed. Results: There were 116 and 105 patients in the 19-gauge FNA and 22-gauge FNB groups, respectively. The median lymph node size was significantly larger in the 19-gauge FNA group (29 mm vs. 23 mm, P < 0.01). Cytological and histological accuracies were significantly higher in the 19-gauge FNA group (91% vs. 63%, P < 0.01; 93% vs. 82%, P = 0.01). Multivariate logistic regression analysis showed that the use of 19-gauge FNA was significantly associated with diagnostic accuracy (cytology: odds ratio = 5.72, P < 0.01; histology: odds ratio = 3.38, P < 0.01). For malignant lymphoma diagnosis, immunohistochemical evaluation rates were similar between groups, whereas flow cytometry and cytogenetic sensitivities were significantly higher with 19-gauge FNA (90% vs . 55%, P < 0.01; and 68% vs. 14%, P < 0.01). Post-puncture infection was observed in only 1 patient in the 19-gauge FNA group. Conclusion: The use of 19-gauge FNA needles appeared to be a good option for diagnosing lymphadenopathy, considering that no significant difference was observed in the occurrence of adverse events.
Background and Aim Gastrointestinal endoscopy is resource-intensive, but no carbon footprint data have been reported from a Japanese facility, and published estimates differ widely in system boundary. We quantified the operational carbon footprint of an endoscopy unit at a Japanese regional hospital and identified which emission sources are amenable to unit-level intervention.Methods In this retrospective single-center study, we analyzed 794 consecutive procedures performed over 5 months at a 150-bed regional public hospital. Emissions from electricity, patient travel, medical waste, consumables, reprocessing chemicals, medical gas, and water were estimated according to the Greenhouse Gas Protocol using Japanese national emission factors and published life-cycle data. Patient travel was aggregated at the procedure level under two scenarios: procedure-day travel only (Scenario A) and visit-count-corrected travel (Scenario B). Sensitivity analyses addressed transport mode, air-conditioning load factor, and waste composition.Results The operational carbon footprint was 6537.5 kg CO2e (CO2e) (8.23 kg CO2e per procedure) in Scenario A and 8042.1 kg CO2e (10.13 kg CO2e per procedure) in Scenario B. In Scenario B, electricity was the largest source (38.8%), followed by patient travel (35.3%) and medical waste (13.5%). Air conditioning accounted for 69.3% of electricity use. Waste generation was 0.80 kg per procedure, of which suction fluid bags represented 36.7%.Conclusions Electricity, dominated by air conditioning, was the largest operational emission source and is directly modifiable by the unit. Patient travel was of comparable magnitude but reflects healthcare access geography rather than endoscopic practice.
Laryngopharyngeal reflux disease (LPRD) lacks effective targeted treatments, as conventional proton pump inhibitors cannot alleviate bile acid-induced mucosal damage and epithelial-mesenchymal transition (EMT). This study aimed to explore the mechanism of acidic bile-mediated LPRD progression and the therapeutic potential of isoquercitrin. An acidic bile-stimulated HHPC cell model and a pyloric ligation-induced rat LPRD model were established. High-throughput screening was used to identify optimal active monomers. Multiple molecular biological assays, molecular docking, microscale thermophoresis, and luciferase reporter assays were performed to verify protein binding and signaling regulation. Gradient-dose isoquercitrin treatment was applied for in vitro and in vivo validation. Pathologically, acidic bile (pH 4.0) disrupted pharyngeal epithelial barrier integrity, decreased E-cadherin expression, and induced EMT by activating the ASIC3/RhoA/beta-catenin positive feedback loop, in which beta-catenin/TCF/LEF further transcriptionally upregulated ASIC3. High-throughput screening confirmed isoquercitrin (IC50 = 34.2 mu M) as the optimal anti-EMT monomer. Mechanistically, isoquercitrin directly bound the N426/S425 sites of beta-catenin, restrained beta-catenin nuclear translocation, and thereby blocked the positive feedback cascade, restored epithelial barrier homeostasis, and reversed bile-induced EMT. Consistently, in vivo LPRD models verified that isoquercitrin dose-dependently attenuated inflammatory infiltration, rescued pharyngeal tissue structural damage, downregulated ASIC3, and recovered E-cadherin expression. In conclusion, isoquercitrin ameliorates LPRD by inhibiting EMT via targeting the ASIC3/RhoA/beta-catenin feedback pathway. These findings identify isoquercitrin as a novel therapeutic candidate for LPRD.
Background and Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global population and is a major health concern. Liver sinusoidal endothelial cells (LSECs) undergo morphological and functional alterations during MASLD progression, resulting in endotheliopathy characterized by pro-inflammatory phenotypes. We hypothesize that lipotoxicity synergistically exacerbates LSEC dysfunction in MASLD via IL-6 trans-signaling.Methods Human adipocytes were treated with palmitic acid (PA). Human LSECs were treated with PA and the IL-6/soluble IL-6 receptor (sIL-6R) complex. Western blotting, qRT-PCR, RNA sequencing, transwell assays, and immunofluorescence were performed to examine inflammatory responses. MASLD model mice were established using a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) to validate the in vivo results. Alterations in LSEC morphology were examined by western blotting, histology, and electron microscopy.Results PA promoted IL-6 secretion from adipocytes. In LSECs, PA increased NF kappa B phosphorylation, whereas co-stimulation with PA and IL-6/sIL-6R complex synergistically enhanced activator of transcription 3 (STAT3) phosphorylation and upregulated inflammatory cytokines, chemokines, and adhesion molecules, including VCAM1. Furthermore, RNA sequencing showed concurrent NF kappa B and Janus kinase (JAK)/STAT pathway activation. This synergistic effect promoted neutrophil migration and VCAM1 expression under in vitro conditions. In the MASLD mouse model, hepatic IL-6 expression was elevated, accompanied by steatosis, increased transaminase levels, and inflammatory cell infiltration, along with increased VCAM1 expression and sinusoidal capillarization characterized by upregulated CD34 and downregulated CD32b and LYVE-1.Conclusion Lipotoxicity-amplified IL-6 trans-signaling synergistically exacerbates LSEC endotheliopathy and promotes leukocyte recruitment and liver injury, contributing to MASLD progression and providing novel insights into its pathogenesis.